Author:
Sohn S K,Kim J G,Kim D H,Lee N Y,Suh J S,Lee K B
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference24 articles.
1. Barrett J, Bahceci E, Childs R et al. High CD34+ cell dose lowers relapse risk in standard and high-risk recipients of allogeneic bone marrow or peripheral blood stem cell transplants (PBSCT). Blood 1998; 92: 139a [abstract].
2. Mavroudis D, Read E, Cottler-Fox M et al. CD34+ cell dose predicts survival, post transplant mobidity and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223–3229.
3. Singhal S, Powles R, Treleaven J et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000; 26: 489–496.
4. Przepiorka D, Anderlini P, Saliba R et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695–1700.
5. Bittencourt H, Rocha V, Chevret S et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99: 2726–2733.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献